非小细胞肺癌患者血清中白介素-6和白介素-17的水平测定

目的探讨非小细胞肺癌（NSCLC）血清中白介素-6和IL-17的水平及临床意义。方法采用双抗体夹心ELISA法检测52例NSCLC患者和25例健康体检者血清中IL-6和IL-17的水平。〈br〉 结果 NSCLC患者血清中IL-6和IL-17水平均高于健康体检者（P〈0.05）。NSCLC患者血清中IL-6和IL-17水平高低与患者的临床分期、分化程度、淋巴结转移有关（P〈0.05）。结论 IL-6和IL-17可能参与了NSCLC发生发展的病理生理学过程，两者水平检测可用于HIE的病情监测和预后评估。

Levels of interleukin-6 and interleukin-17 in the serum of patients with non-small-cell lung cancer

Objective To investigate the levels of interleukin （IL）-6 and IL-17 in the serum of patients with non-small-cell lung cancer （NSCLC） and their clinical significance. Methods A double antibody sandwich ELISA assay was used to detected the serum IL-6 and IL-17 levels in the 52 cases of NSCLC and 25 cases of healthy subjects. Results The serum IL-6 and IL-17 levels of patients with NSCLC were higher than those of the healthy subjects （P＆lt;0.05）. The levels of IL-6 and IL-17 were significantly related with the clinical stage, differentiation degree and lymph node metastasis in the patients with NSCLC （P＆lt;0.05）. Conclusion IL-6 and IL-17 may be involved in the development and improvement of NSCLC, they can be used to evaluate the condition and prognosis of NSCLC.